The Comfort Premium

Hannah (not her real name) is 58 years old. She writes computer code (it’s a good living for now), but she has cancer. When her oncologist mentioned a new formulation of her immunotherapy, one she could take as a quick injection instead of spending hours in an infusion chair every few weeks, Hannah was very interested. Less time away from work. Less time sitting alone under fluorescent lights. Less of everything that reminds her she’s sick.

Then she found out what the new, more convenient treatment would cost her.

The injectable version of her drug — clinically identical to the intravenous one, same medicine — carried a price tag tens of thousands of dollars more per year. Not because it worked better. Not because it kept patients alive longer, or shrank tumors more reliably, or spared them side effects. Simply because it was easier to give.

Oncologist and researcher Bishal Gyawali recently published an essay in the Journal of Clinical Oncology Practice asking a question that sounds obvious, but rarely gets asked in cancer medicine: What exactly are patients paying for when we call something "more convenient"? The point is that convenience is not nothing, but it’s not automatically worth a massive price increase.

Financial toxicity is the way cancer costs can attack a patient's savings just as chemotherapy attacks cancer cells. The common approach is that drug companies repackage existing therapies in a new delivery form, label it an innovation, and charge accordingly. Subcutaneous instead of intravenous. A pill instead of an infusion. Same molecule, more profit.

Hannah has decent insurance, but decent insurance in America still means deductibles, copays, and out-of-pocket maximums that run into the thousands. She has to weigh an afternoon in the infusion suite — inconvenient, exhausting, real — against a financial hit that could outlast her.

We need to treat convenience as a patient value while refusing to let it serve as a blank check. The doctors can prescribe either drug, the usual or the more convenient. Of course, doctors can’t dismiss Hannah's time in that infusion chair. But meaningful convenience — the kind that genuinely improves quality of life, reduces caregiver burden, or expands access for patients who struggle to reach a clinic — deserves honest pricing. What it should not do is justify a staggering markup that prices some patients out entirely.

Hannah's decision is difficult and compelling. She is educated, employed, and insured. She can advocate for herself in ways many cancer patients cannot. Just imagine a patient who is not so capable.

Convenience matters. So does surviving treatment without going broke. When the two collide, we owe all patients honest, equitable pricing.

— Dr. Michael Wilkes with a Second Opinion

Thanks to readers and listeners like you, this newsletter is free for everyone. If this newsletter has ever sparked discussions about medical ethics and issues for you, consider supporting it to keep it going.